These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 20854304)

  • 1. Optimizing ICD programming for shock reduction.
    Schwab JO
    Fundam Clin Pharmacol; 2010 Oct; 24(5):653-9. PubMed ID: 20854304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avoid delivering therapies for nonsustained fast ventricular tachyarrhythmia in patients with implantable cardioverter/defibrillator: the ADVANCE III Trial.
    Schwab JO; Gasparini M; Lunati M; Proclemer A; Kaup B; Santi E; Ligorio G; Klersy C; DE Sousa J; Okreglicki A; Arenal A; Wijffels M; Lemke B
    J Cardiovasc Electrophysiol; 2009 Jun; 20(6):663-6. PubMed ID: 19175450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results.
    Wathen MS; DeGroot PJ; Sweeney MO; Stark AJ; Otterness MF; Adkisson WO; Canby RC; Khalighi K; Machado C; Rubenstein DS; Volosin KJ;
    Circulation; 2004 Oct; 110(17):2591-6. PubMed ID: 15492306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.
    Wilkoff BL; Williamson BD; Stern RS; Moore SL; Lu F; Lee SW; Birgersdotter-Green UM; Wathen MS; Van Gelder IC; Heubner BM; Brown ML; Holloman KK;
    J Am Coll Cardiol; 2008 Aug; 52(7):541-50. PubMed ID: 18687248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) trial.
    Sweeney MO; Wathen MS; Volosin K; Abdalla I; DeGroot PJ; Otterness MF; Stark AJ
    Circulation; 2005 Jun; 111(22):2898-905. PubMed ID: 15927965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implantable cardioverter defibrillator shock reduction using new antitachycardia pacing therapies.
    Wathen M
    Am Heart J; 2007 Apr; 153(4 Suppl):44-52. PubMed ID: 17394902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in tachyarrhythmia detection and implantable cardioverter defibrillator therapy by primary or secondary prevention indication in cardiac resynchronization therapy patients.
    Wilkoff BL; Hess M; Young J; Abraham WT
    J Cardiovasc Electrophysiol; 2004 Sep; 15(9):1002-9. PubMed ID: 15363071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized study to compare ramp versus burst antitachycardia pacing therapies to treat fast ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators: the PITAGORA ICD trial.
    Gulizia MM; Piraino L; Scherillo M; Puntrello C; Vasco C; Scianaro MC; Mascia F; Pensabene O; Giglia S; Chiarandà G; Vaccaro I; Mangiameli S; Corrao D; Santi E; Grammatico A;
    Circ Arrhythm Electrophysiol; 2009 Apr; 2(2):146-53. PubMed ID: 19808459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of ventricular tachyarrhythmia by treatment of atrial fibrillation in ICD patients with dual-chamber implantable cardioverter/defibrillators capable of atrial therapy delivery: the REVERT-AF Study.
    Gradaus R; Seidl K; Korte T; Himmrich E; Wieneke H; Schuchert A; Bauer W; Gerss J; Wollmann CG; Borggrefe M; Böcker D
    Europace; 2007 Jul; 9(7):534-9. PubMed ID: 17440005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and causes of inappropriate detection and therapy by implantable defibrillators of cardioversion in patients with ventricular tachyarrhythmia.
    Chen RH; Chen KP; Wang FZ; Hua W; Chen X; Zhang S
    Chin Med J (Engl); 2006 Apr; 119(7):557-63. PubMed ID: 16620696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High incidence of appropriate and inappropriate ICD therapies in children and adolescents with implantable cardioverter defibrillator.
    Korte T; Köditz H; Niehaus M; Paul T; Tebbenjohanns J
    Pacing Clin Electrophysiol; 2004 Jul; 27(7):924-32. PubMed ID: 15271011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of quality of life by means of antitachy pacing: from PainFREE to the ADVANCE-D Trial.
    Lunati M; Defaye P; Mermi J; Garcia-Alberola A; Merino JL; Arenal A; Cappato R; Navarro X; Passardi M; Santini M
    Pacing Clin Electrophysiol; 2006 Dec; 29 Suppl 2():S35-9. PubMed ID: 17169131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitachycardia pacing for spontaneous rapid ventricular tachycardia in patients with prophylactic cardioverter-defibrillator therapy.
    Grimm W; Plachta E; Maisch B
    Pacing Clin Electrophysiol; 2006 Jul; 29(7):759-64. PubMed ID: 16884513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and clinical relevance of slow ventricular tachycardia in implantable cardioverter-defibrillator recipients: an international multicenter prospective study.
    Sadoul N; Mletzko R; Anselme F; Bowes R; Schöls W; Kouakam C; Casteigneau G; Luise R; Iscolo N; Aliot E;
    Circulation; 2005 Aug; 112(7):946-53. PubMed ID: 16103252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, efficacy, and performance of new discrimination algorithms to reduce inappropriate and unnecessary shocks: the PainFree SST clinical study design.
    Auricchio A; Meijer A; Kurita T; Schloss E; Brinkman K; Claessens-van Ooijen M; Sterns L
    Europace; 2011 Oct; 13(10):1484-93. PubMed ID: 21669960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of upgrade to cardiac resynchronization therapy on ventricular arrhythmia frequency in patients with implantable cardioverter-defibrillators.
    Ermis C; Seutter R; Zhu AX; Benditt LC; VanHeel L; Sakaguchi S; Lurie KG; Lu F; Benditt DG
    J Am Coll Cardiol; 2005 Dec; 46(12):2258-63. PubMed ID: 16360055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of empiric to physician-tailored programming of implantable cardioverter-defibrillators: results from the prospective randomized multicenter EMPIRIC trial.
    Wilkoff BL; Ousdigian KT; Sterns LD; Wang ZJ; Wilson RD; Morgan JM;
    J Am Coll Cardiol; 2006 Jul; 48(2):330-9. PubMed ID: 16843184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or ventricular fibrillation in Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients.
    Daubert JP; Zareba W; Hall WJ; Schuger C; Corsello A; Leon AR; Andrews ML; McNitt S; Huang DT; Moss AJ;
    J Am Coll Cardiol; 2006 Jan; 47(1):98-107. PubMed ID: 16386671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical evaluation of a dual chamber implantable cardioverter-defibrillator].
    Kazmierczak J; Tavernier R; De Sutter J; Jordaens L
    Pol Merkur Lekarski; 2000 Aug; 9(50):522-6. PubMed ID: 11081315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial: rationale, design, results, clinical implications and lessons for future trials.
    Wilkoff BL;
    Card Electrophysiol Rev; 2003 Dec; 7(4):468-72. PubMed ID: 15071277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.